Open AccessCTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
Author(s) -
Jianda Yuan,
Brian Ginsberg,
David B. Page,
Yanyun Li,
Teresa Rasalan,
Humilidad F. Gallardo,
Yinyan Xu,
Sylvia Adams,
Nina Bhardwaj,
Klaus J. Busam,
Lloyd J. Old,
James P. Allison,
Achim A. Jungbluth,
Jedd D. Wolchok
Publication year - 2011
Publication title -
cancer immunology, immunotherapy/cancer immunology and immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.389
H-Index - 115
eISSN - 1432-0851
pISSN - 0340-7004
DOI - 10.1007/s00262-011-1011-9
Subject(s) - blockade , melanoma , ctla 4 , antigen , immunology , cd8 , cytotoxic t cell , medicine , cancer research , biology , t cell , immune system , receptor , genetics , in vitro
Anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies, such as ipilimumab, have generated measurable immune responses to Melan-A, NY-ESO-1, and gp100 antigens in metastatic melanoma. Vaccination against such targets has potential for immunogenicity and may produce an effector-memory T-cell response.